Watson Pharmaceuticals’ TRELSTAR receives FDA approval for treatment of advanced prostate cancer
March 15, 2010 by Prostate Dr.
Multimedia software program developed to help prostate cancer patients make treatment decisions Mount Sinai School of Medicine is leading a study of patients newly-diagnosed with prostate cancer to determine if providing them with multimedia materials can help them make more informed treatment decisions. Michael Diefenbach, Ph.D., Associate Professor of Urology at Mount Sinai School of Medicine developed a multimedia software program designed to help prostate cancer patients and their ... Read more on News-Medical-Net
Related prostate health articles:
- Can Multimedia Lead to More Informed Decisions on Prostate Cancer Treatment?: Watson Pharmaceuticals’ TRELSTAR receives FDA approval for treatment of advanced prostate cancer Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer. Read more on News-Medical-Net Can Multimedia Lead to
- Germany’s University Medical Center Mannheim Accelerates Cancer Care with Elekta’s Monaco Planning Software: Immunovaccine Begins Patient Recruitment For Phase 1 Trial Of DPX-0907 Cancer Vaccine Immunovaccine Inc. (TSX VENTURE:IMV) announced that it has started screening patients for its Phase 1 clinical trial, investigating the company’s therapeutic cancer vaccine, DPX-0907, as a treatment for patients with advanced stage breast, ovarian and prostate cancer. The primary goal of the trial is
- Changing drug therapy can help breast cancer patients get full benefit of tamoxifen treatment: New GreenLight MoJo(TM) Now Delivers 400kJ for More Efficient Laser Therapy to Treat Enlarged Prostate MINNETONKA, Minn., March 25 /PRNewswire-FirstCall/ — American Medical Systems® (AMS) (Nasdaq: AMMD), a leading provider of world-class devices and therapies for both male and female pelvic health, announced the release of GreenLight MoJo, a new software upgrade for its industry-leading GreenLight
- Immunovaccine Begins Patient Recruitment for Phase 1 Trial of DPX-0907 Cancer Vaccine: Immunovaccine Begins Patient Recruitment for Phase 1 Trial of DPX-0907 Cancer Vaccine HALIFAX, NOVA SCOTIA– – Immunovaccine Inc. today announced that it has started screening patients for its Phase 1 clinical trial, investigating the company’s therapeutic cancer vaccine, DPX-0907, as a treatment for patients with advanced stage breast, ovarian and prostate cancer. Read more on CCNMatthews via
- Where Cancer Treatment Takes Place May Influence Outcome: Noscapine can be used as prophylactic treatment for prostate cancer: Study New research has revealed a major breakthrough in the use of cough medicine ingredient noscapine as a prophylactic treatment for prostate cancer. Read more on News-Medical-Net Where Cancer Treatment Takes Place May Influence Outcome Title: Where Cancer Treatment Takes Place May Influence Outcome Category: Health News Created: 3/22/2010
Comments